J&J sees tariff impact from exports to China more than global imports: CFO

Key Points

  • Johnson & Johnson (JNJ) reported a beat on first quarter earnings, with revenue of $21.9 billion and adjusted EPS of $2.69, surpassing Wall Street estimates.
  • The company raised its 2025 sales guidance by $700 million, despite concerns about tariffs and patent expiries.
  • Tariffs, particularly from China, are expected to impact J&J's medical devices business, with an estimated $400 million hit.
  • J&J is dealing with ongoing talc litigation, with a recent court setback, and is now pursuing a different legal strategy.

Summary

Johnson & Johnson (JNJ) announced its first quarter earnings, surpassing Wall Street expectations with a revenue of $21.9 billion and an adjusted EPS of $2.69. Despite these positive results, the company's stock experienced a slight decline. J&J raised its 2025 sales guidance by $700 million, aiming for a growth of 3.3% to 4.3%, even as it navigates challenges like the patent expiry of its key drug Stelara. The company highlighted significant exposure to tariffs in China, Canada, and Mexico, with CFO Joe Wolk estimating a $400 million impact primarily on the medical devices sector due to various tariffs, including those from China. Additionally, J&J is contending with industry-wide issues like pharmaceutical tariffs and the Inflation Reduction Act's impact on Medicare price negotiations. The company also faces ongoing legal battles related to talc litigation, with a recent court rejection of a proposed $10 billion settlement, leading J&J to return $7 billion to its coffers and pursue a new legal strategy expected to unfold by the end of October 2025.

yahoo
April 15, 2025
Stocks
Read article

Related news